Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: David Lenigas answers investor questions in a detailed interview about UKOG, Doriemus, LGC Capital, AfriAg and Angus Energy.


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 182.50Bid: 180.00Ask: 185.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 5.00Spread as %: 2.78%Open: 185.00High: 185.00Low: 182.50Yesterday’s Close: 182.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
182.50

Share Price SpacerBid
180.00

Share Price SpacerAsk
185.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
12,951

Share Price SpacerOpen
185.00

Share Price SpacerHigh
185.00

Share Price SpacerLow
182.50

Share Price SpacerClose
182.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 70.63m £128.90m 1,500

52 Week High 265.00 52 Week High Date 11-SEP-2017
52 Week Low 141.50 52 Week Low Date 3-JAN-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
10 2,022 10,929 -5.214 -35.00 0.00 0.00


London South East Users info for Summit Ther




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

19-Oct-17
13:57:22
180.00
1,923
Sell* 
180.00
185.00
3,461
Trade Type:
Ordinary
Delayed publication
Historical

19-Oct-17
13:57:22
180.00
1,923
Sell* 
180.00
185.00
3,461
Trade Type:
Ordinary

19-Oct-17
13:57:22
180.00
-1,923
Sell* 
180.00
185.00
-3,461
Trade Type:
Ordinary
Deletion
Late reported




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Fri 21:43ChrisatrdgClosing NASDAQ position182.50Buy
A further decline on the NASDAQ tonight now showing £1.76 using an exchange rate of $1.32 to the £.
http://weekherald.com/2017/10/18/summit-therapeutics-plc-smmt-stock-rating-lowered-by-valuengine.html
Looks to me that the above re-rate has done some damage & that the 'previous road show' has not convinced punters that Summit is about to go places.
I sincerely hope that we have positive results in Qtr 1 2018 for DMD.
Fri 09:41Free-MoneyRE: DMD drugs182.50No Opinion
Yes, we are on good ground here. I expect Ezutromid to be successful and prove the concept based on the biomarkers. We'll have to wait and see longer term how it's effects will manifest physically for the boys though... fingers and everything crossed.
But it is very encourage that we have the financing to push the next generation through as quickly as possible now too, which adds a further level of hope and with a bit of luck even more improved efficacy and the boys could look forward to… Read More
Fri 08:21WalkleyDMD drugs185.00No Opinion
From the Muscular Dystrophy UK web site:

"Another potential therapy for DMD is to raise the levels of utrophin protein, as a functional substitute for dystrophin. The potential treatment has been developed in the laboratory of Professor Kay Davies in Oxford.

Despite excellent results in animal models, the first clinical trial in healthy volunteers of a first generation drug SMT C1100 lead to the delivery of insufficient amount of the drug to the muscles. SMT C1100 has since been… Read More
13 Oct '17eurotoInvestors Chronicle190.00No Opinion
Supportive comment in IC re Summit progress
12 Oct '17DavieladRE: webcast190.00No Opinion
Guys, two excellent posts from you today, with first class synopsis of the recent info released. Those of us such as myself, who are not so au fait with the science, or the processes involved in pursuing the Company's objectives, are indebted to you for your input, and for sharing your comments with us.
12 Oct '17gmccRE: webcast192.50No Opinion
Hi rotivatorman - Thanks very much very comprehensive summary really appreciated - agree !

If I may add : Firstly good to hear contributions from new speakers , Summit have gathered a strong team of in-house professionals & external experts .

DMD presentations . Wow this is indeed a very complicated process ,

Ground breaking cutting edge new data analysis , Summit kind of admitted learning as they go along - Proving continuous utrophin… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.